Taijyu Satoh1, Longfei Wang1, Cristina Espinosa-Diez1, Bing Wang2, Scott A Hahn1, Kentaro Noda3, Elizabeth R Rochon1, Matthew R Dent, Andrea R Levine4, Jeffrey J Baust1, Samuel Wyman5, Yijen L Wu5, Georgios A Triantafyllou6, Ying Tang1,7, Mike Reynolds1, Sruti Shiva1,8, Cynthia St Hilaire1,7,9, Delphine Gomez1,7, Dmitry A Goncharov1,10, Elena A Goncharova1,9,10, Stephen Y Chan1,7, Adam C Straub1,8, Yen-Chun Lai11, Charles F McTiernan1, Mark T Gladwin1,6. 1. Pittsburgh Heart, Lung and Blood Vascular Medicine Institute (T.S., L.W., C.E.-D., S.A.H., E.R.R., M.R.D., J.J.B., Y.T., M.R., S.S., C.S.H., D.G., D.A.G., E.A.G., S.Y.C., A.C.S., C.F.M., M.T.G.), University of Pittsburgh School of Medicine, PA. 2. Department of Orthopedic Surgery (B.W.), University of Pittsburgh, PA. 3. Division of Lung Transplant and Lung Failure, Department of Cardiothoracic Surgery (K.N.), University of Pittsburgh, PA. 4. Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore (A.L.). 5. Rangos Research Center Animal Imaging Core and Developmental Biology (S.W., Y.L.W.), University of Pittsburgh, PA. 6. Division of Pulmonary, Allergy and Critical Care Medicine (G.A.T., M.T.G.), University of Pittsburgh School of Medicine, PA. 7. Division of Cardiology (Y.T., C.S.H., D.G., S.Y.C.), University of Pittsburgh School of Medicine, PA. 8. Department of Pharmacology and Chemical Biology (S.S., A.C.S.), University of Pittsburgh School of Medicine, PA. 9. Department of Bioengineering (C.S.H., E.A.G.), University of Pittsburgh School of Medicine, PA. 10. Division of Pulmonary, Critical Care and Sleep Medicine, University of California Davis (D.A.G., E.A.G.). 11. Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indiana University School of Medicine, Indianapolis (Y.-C.L.).
Abstract
BACKGROUND: Many patients with heart failure with preserved ejection fraction have metabolic syndrome and develop exercise-induced pulmonary hypertension (EIPH). Increases in pulmonary vascular resistance in patients with heart failure with preserved ejection fraction portend a poor prognosis; this phenotype is referred to as combined precapillary and postcapillary pulmonary hypertension (CpcPH). Therapeutic trials for EIPH and CpcPH have been disappointing, suggesting the need for strategies that target upstream mechanisms of disease. This work reports novel rat EIPH models and mechanisms of pulmonary vascular dysfunction centered around the transcriptional repression of the soluble guanylate cyclase (sGC) enzyme in pulmonary artery (PA) smooth muscle cells. METHODS: We used obese ZSF-1 leptin-receptor knockout rats (heart failure with preserved ejection fraction model), obese ZSF-1 rats treated with SU5416 to stimulate resting pulmonary hypertension (obese+sugen, CpcPH model), and lean ZSF-1 rats (controls). Right and left ventricular hemodynamics were evaluated using implanted catheters during treadmill exercise. PA function was evaluated with magnetic resonance imaging and myography. Overexpression of nuclear factor Y α subunit (NFYA), a transcriptional enhancer of sGC β1 subunit (sGCβ1), was performed by PA delivery of adeno-associated virus 6. Treatment groups received the SGLT2 inhibitor empagliflozin in drinking water. PA smooth muscle cells from rats and humans were cultured with palmitic acid, glucose, and insulin to induce metabolic stress. RESULTS: Obese rats showed normal resting right ventricular systolic pressures, which significantly increased during exercise, modeling EIPH. Obese+sugen rats showed anatomic PA remodeling and developed elevated right ventricular systolic pressure at rest, which was exacerbated with exercise, modeling CpcPH. Myography and magnetic resonance imaging during dobutamine challenge revealed PA functional impairment of both obese groups. PAs of obese rats produced reactive oxygen species and decreased sGCβ1 expression. Mechanistically, cultured PA smooth muscle cells from obese rats and humans with diabetes or treated with palmitic acid, glucose, and insulin showed increased mitochondrial reactive oxygen species, which enhanced miR-193b-dependent RNA degradation of nuclear factor Y α subunit (NFYA), resulting in decreased sGCβ1-cGMP signaling. Forced NYFA expression by adeno-associated virus 6 delivery increased sGCβ1 levels and improved exercise pulmonary hypertension in obese+sugen rats. Treatment of obese+sugen rats with empagliflozin improved metabolic syndrome, reduced mitochondrial reactive oxygen species and miR-193b levels, restored NFYA/sGC activity, and prevented EIPH. CONCLUSIONS: In heart failure with preserved ejection fraction and CpcPH models, metabolic syndrome contributes to pulmonary vascular dysfunction and EIPH through enhanced reactive oxygen species and miR-193b expression, which downregulates NFYA-dependent sGCβ1 expression. Adeno-associated virus-mediated NFYA overexpression and SGLT2 inhibition restore NFYA-sGCβ1-cGMP signaling and ameliorate EIPH.
BACKGROUND: Many patients with heart failure with preserved ejection fraction have metabolic syndrome and develop exercise-induced pulmonary hypertension (EIPH). Increases in pulmonary vascular resistance in patients with heart failure with preserved ejection fraction portend a poor prognosis; this phenotype is referred to as combined precapillary and postcapillary pulmonary hypertension (CpcPH). Therapeutic trials for EIPH and CpcPH have been disappointing, suggesting the need for strategies that target upstream mechanisms of disease. This work reports novel rat EIPH models and mechanisms of pulmonary vascular dysfunction centered around the transcriptional repression of the soluble guanylate cyclase (sGC) enzyme in pulmonary artery (PA) smooth muscle cells. METHODS: We used obese ZSF-1 leptin-receptor knockout rats (heart failure with preserved ejection fraction model), obese ZSF-1 rats treated with SU5416 to stimulate resting pulmonary hypertension (obese+sugen, CpcPH model), and lean ZSF-1 rats (controls). Right and left ventricular hemodynamics were evaluated using implanted catheters during treadmill exercise. PA function was evaluated with magnetic resonance imaging and myography. Overexpression of nuclear factor Y α subunit (NFYA), a transcriptional enhancer of sGC β1 subunit (sGCβ1), was performed by PA delivery of adeno-associated virus 6. Treatment groups received the SGLT2 inhibitor empagliflozin in drinking water. PA smooth muscle cells from rats and humans were cultured with palmitic acid, glucose, and insulin to induce metabolic stress. RESULTS: Obese rats showed normal resting right ventricular systolic pressures, which significantly increased during exercise, modeling EIPH. Obese+sugen rats showed anatomic PA remodeling and developed elevated right ventricular systolic pressure at rest, which was exacerbated with exercise, modeling CpcPH. Myography and magnetic resonance imaging during dobutamine challenge revealed PA functional impairment of both obese groups. PAs of obese rats produced reactive oxygen species and decreased sGCβ1 expression. Mechanistically, cultured PA smooth muscle cells from obese rats and humans with diabetes or treated with palmitic acid, glucose, and insulin showed increased mitochondrial reactive oxygen species, which enhanced miR-193b-dependent RNA degradation of nuclear factor Y α subunit (NFYA), resulting in decreased sGCβ1-cGMP signaling. Forced NYFA expression by adeno-associated virus 6 delivery increased sGCβ1 levels and improved exercise pulmonary hypertension in obese+sugen rats. Treatment of obese+sugen rats with empagliflozin improved metabolic syndrome, reduced mitochondrial reactive oxygen species and miR-193b levels, restored NFYA/sGC activity, and prevented EIPH. CONCLUSIONS: In heart failure with preserved ejection fraction and CpcPH models, metabolic syndrome contributes to pulmonary vascular dysfunction and EIPH through enhanced reactive oxygen species and miR-193b expression, which downregulates NFYA-dependent sGCβ1 expression. Adeno-associated virus-mediated NFYA overexpression and SGLT2 inhibition restore NFYA-sGCβ1-cGMP signaling and ameliorate EIPH.
Authors: Thomas M Gorter; Masaru Obokata; Yogesh N V Reddy; Vojtech Melenovsky; Barry A Borlaug Journal: Eur Heart J Date: 2018-08-07 Impact factor: 29.983
Authors: Gabor Kovacs; Philippe Herve; Joan Albert Barbera; Ari Chaouat; Denis Chemla; Robin Condliffe; Gilles Garcia; Ekkehard Grünig; Luke Howard; Marc Humbert; Edmund Lau; Pierantonio Laveneziana; Gregory D Lewis; Robert Naeije; Andrew Peacock; Stephan Rosenkranz; Rajeev Saggar; Silvia Ulrich; Dario Vizza; Anton Vonk Noordegraaf; Horst Olschewski Journal: Eur Respir J Date: 2017-11-22 Impact factor: 16.671
Authors: Mizanur M Rahaman; Anh T Nguyen; Megan P Miller; Scott A Hahn; Courtney Sparacino-Watkins; Soma Jobbagy; Nolan T Carew; Nadiezhda Cantu-Medellin; Katherine C Wood; Catherine J Baty; Francisco J Schopfer; Eric E Kelley; Mark T Gladwin; Emil Martin; Adam C Straub Journal: Circ Res Date: 2017-06-05 Impact factor: 17.367
Authors: Iraida G Sharina; Emil Martin; Anthony Thomas; Karen L Uray; Ferid Murad Journal: Proc Natl Acad Sci U S A Date: 2003-09-22 Impact factor: 11.205
Authors: Marius M Hoeper; Joan Albert Barberà; Richard N Channick; Paul M Hassoun; Irene M Lang; Alessandra Manes; Fernando J Martinez; Robert Naeije; Horst Olschewski; Joanna Pepke-Zaba; Margaret M Redfield; Ivan M Robbins; Rogério Souza; Adam Torbicki; Michael McGoon Journal: J Am Coll Cardiol Date: 2009-06-30 Impact factor: 24.094
Authors: Francisco Teixeira-Coelho; Cletiana Gonçalves Fonseca; Nicolas Henrique Santos Barbosa; Filipe Ferreira Vaz; Letícia Maria de Souza Cordeiro; Cândido Celso Coimbra; Washington Pires; Danusa Dias Soares; Samuel Penna Wanner Journal: PLoS One Date: 2017-08-25 Impact factor: 3.240
Authors: Joseph C Galley; Megan P Miller; Subramaniam Sanker; Mingjun Liu; Iraida Sharina; Emil Martin; Delphine Gomez; Adam C Straub Journal: Am J Physiol Heart Circ Physiol Date: 2022-01-28 Impact factor: 4.733
Authors: Marco Guazzi; Matthias Wilhelm; Martin Halle; Emeline Van Craenenbroeck; Hareld Kemps; Rudolph A de Boer; Andrew J S Coats; Lars Lund; Donna Mancini; Barry Borlaug; Gerasimos Filippatos; Burkert Pieske Journal: Eur J Heart Fail Date: 2022-07-31 Impact factor: 17.349